<DOC>
	<DOCNO>NCT01255215</DOCNO>
	<brief_summary>Despite use highly effective anti-malarial medication , 10-30 % African child severe malaria die , underscore need adjunctive therapy apply endemic area . A clinical trial adjunctive inhale nitric oxide ( iNO ) severe malaria warrant basis firm proof concept animal study human study use NO donor L-arginine , together evidence safety clinical experience trial iNO condition . Our objective determine whether supplemental iNO ( 80 ppm ) addition Ugandan Standard Care treatment reduces level Angiopoietin-2 ( Ang-2 ) , quantitative biomarker malaria severity , child severe malaria compare Standard Care treatment alone . We conduct randomize placebo-controlled trial among child 1-10 year age admit Jinja Hospital ( Uganda ) severe malaria test efficacy inhale nitric oxide severe malaria .</brief_summary>
	<brief_title>Inhaled Nitric Oxide Adjunctive Therapy Severe Malaria : Randomized Controlled Trial</brief_title>
	<detailed_description>Severe malaria remain major cause global morbidity mortality . While use artemisinin-based antimalarial therapy improve outcome severe malaria , mortality rate remain high . Adjunctive therapy target underlie pathophysiology severe malaria may reduce morbidity mortality . Endothelial activation play central role pathogenesis severe malaria , angiogenic factor angiopoietin-1 ( Ang-1 ) angiopoietin-2 ( Ang-2 ) recently show function key regulator . Nitric oxide ( NO ) major inhibitor Ang-2 release endothelium show decrease endothelial inflammation reduce adhesion parasitized erythrocyte . Low-flow inhale nitric oxide gas ( iNO ) US FDA-approved treatment hypoxic respiratory failure neonates . Based compel data efficacy iNO experimental cerebral malaria animal model , couple document safety iNO clinical practice trial disease , propose randomized clinical trial iNO adjunctive treatment severe malaria Ugandan child .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<criteria>Age 110 year Positive malaria rapid diagnostic test presence feature severe malaria Willing able complete follow schedule study 14 day 6 month hospital discharge Baseline methemoglobinemia Known renal , cardiac , hepatic disease chronic illness like diabetes , epilepsy , cerebral palsy , clinical AIDS Severe malnutrition Severe malarial anemia without sign severe malaria</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>malaria</keyword>
	<keyword>child</keyword>
</DOC>